Sebastiano Buti

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 86

Top Topics

Systematic Review

Tyrosine Kinase

Prognostic Factors

Renal Cell Carcinoma

Top Venues

Future oncology (London, England)

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau". Human vaccines & immunotherapeutics 20 (1) (2024)
Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau". Human vaccines & immunotherapeutics 20 (1) (2024)
Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau". Human vaccines & immunotherapeutics 20 (1) (2024)
Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt
Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nature reviews. Urology 21 (7) (2024)
Alessandra Damassi, Malvina Cremante, Alessio Signori, Sara Elena Rebuzzi, Andrea Malgeri, Marilena Di Napoli, Orazio Caffo, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Veronica Prati, Marianna Tudini, Francesco Atzori, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Fabio Catalano, Veronica Murianni, Pasquale Rescigno, Giuseppe Luigi Banna, Giuseppe Fornarini, Sebastiano Buti
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. Immunotherapy (2024)
Matteo Santoni, Hideki Takeshita, Francesco Massari, Aristotelis Bamias, Linda Cerbone, Ondrej Fiala, Veronica Mollica, Sebastiano Buti, Angela Santoni, Joaquim Bellmunt
Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nature reviews. Urology (2024)
Ondrej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate. Cancer medicine 13 (1) (2024)
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Maruzzo Marco, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future oncology (London, England) (2024)
Ondrej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate. Cancer medicine (2024)
Michele Maffezzoli, Sebastiano Buti
Prognostication for surgically treated papillary renalcell carcinoma: which model is the optimal choice? Future oncology (London, England) (2024)
Katsuhiko Nara, Satoru Taguchi, Sebastiano Buti, Taketo Kawai, Yukari Uemura, Takehito Yamamoto, Haruki Kume, Tappei Takada
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis. Journal for immunotherapy of cancer 12 (3) (2024)
Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, Giuseppe Fornarini, Marco Maruzzo, Paolo Andrea Zucali, Fabio Catalano, Ludovica Antonj, Marianna Tudini, Lucia Fratino, Andrea Malgeri, Pasquale Rescigno, Alessio Signori, Alessandro Acunzo, Enrico Maria Silini, Giulia Mazzaschi, Sebastiano Buti
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study. Immunotherapy (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Maruzzo Marco, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future oncology (London, England) (2024)
Katsuhiko Nara, Satoru Taguchi, Sebastiano Buti, Taketo Kawai, Yukari Uemura, Takehito Yamamoto, Haruki Kume, Tappei Takada
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis. Journal for immunotherapy of cancer 12 (3) (2024)
Fabiana Perrone, Federica Pecci, Michele Maffezzoli, Giulia Claire Giudice, Valeria Cognigni, Giulia Mazzaschi, Luca Cantini, Luca Santamaria, Francesco Paoloni, Marco Luigi Bruno Rocchi, Matilde Coriano', Alessandro Acunzo, Federico Quaini, Marcello Tiseo, Saini S Kamal, Rossana Berardi, Sebastiano Buti
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy. Immunotherapy (2024)
Ondrej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate. Cancer medicine (2024)
Chiara Ciccarese, Thomas Büttner, Linda Cerbone, Ilaria Zampiva, Fernando Sabino M Monteiro, Umberto Basso, Martin Pichler, Maria Giuseppa Vitale, Ondrej Fiala, Giandomenico Roviello, Ray Manneh Kopp, Francesco Carrozza, Renate Pichler, Francesco Grillone, Esther Pérez Calabuig, Annalisa Zeppellini, Zsófia Küronya, Luca Galli, Gaetano Facchini, Kaisa Sunela, Alessandra Mosca, Javier Molina-Cerrillo, Gian Paolo Spinelli, Jawaher Ansari, Alessandro Scala, Veronica Mollica, Enrique Grande, Sebastiano Buti, Ravindran Kanesvaran, Roubini Zakopoulou, Aristotelis Bamias, Mimma Rizzo, Francesco Massari, Roberto Iacovelli, Matteo Santoni
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study). International journal of cancer (2024)
Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau". Human vaccines & immunotherapeutics 20 (1) (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Maruzzo Marco, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). Future oncology (London, England) (2024)
Michele Maffezzoli, Sebastiano Buti
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice? Future oncology (London, England) 20 (3) (2024)
Katsuhiko Nara, Satoru Taguchi, Sebastiano Buti, Taketo Kawai, Yukari Uemura, Takehito Yamamoto, Haruki Kume, Tappei Takada
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis. Journal for immunotherapy of cancer 12 (3) (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Ondrej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate. Cancer medicine (2024)
Michele Maffezzoli, Sebastiano Buti
Prognostication for surgically treated papillary renal cell carcinoma: which model is the optimal choice? Future oncology (London, England) 20 (3) (2024)
Khalil Choucair, Caroline Nebhan, Alessio Cortellini, Stijn Hentzen, Yinghong Wang, Cynthia Liu, Raffaele Giusti, Marco Filetti, Paolo Antonio Ascierto, Vito Vanella, Domenico Galetta, Annamaria Catino, Nour Al-Bzour, Azhar Saeed, Ludimila Cavalcante, Pamela Pizzutilo, Carlo Genova, Melissa Bersanelli, Sebastiano Buti, Douglas B Johnson, Claudia Angela Maria Fulgenzi, David James Pinato, Maluki Radford, Chul Kim, Abdul Rafeh Naqash, Anwaar Saeed
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival. Cancers 15 (20) (2023)
Veronica Murianni, Luigi Cerbone, Pasquale Rescigno, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Guido Pesola, Giuseppe Luigi Banna, Sebastiano Buti, Alessio Signori, Giuseppe Fornarini, Sara Elena Rebuzzi
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. Immunotherapy 14 (18) (2023)
Daniele Santini, Giuseppe Luigi Banna, Sebastiano Buti, Luca Isella, Marco Stellato, Michela Roberto, Roberto Iacovelli
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts. Current oncology reports (2023)
Veronica Murianni, Luigi Cerbone, Pasquale Rescigno, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Guido Pesola, Giuseppe Luigi Banna, Sebastiano Buti, Alessio Signori, Giuseppe Fornarini, Sara Elena Rebuzzi
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. Immunotherapy 14 (18) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Malvina Cremante, Silvia Puglisi, Annalice Gandini, Antonio Guadagno, Fabio Catalano, Alessandra Damassi, Veronica Murianni, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Sebastiano Buti, Sara Elena Rebuzzi, Pasquale Rescigno, Giuseppe Fornarini
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica Teresa Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Marina Chiara Garassino, Andrea Botticelli, Alain J Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel Laurence Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo Antonio Ascierto, Corrado Ficorella, David James Pinato
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Veronica Murianni, Luigi Cerbone, Pasquale Rescigno, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Guido Pesola, Giuseppe Luigi Banna, Sebastiano Buti, Alessio Signori, Giuseppe Fornarini, Sara Elena Rebuzzi
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. Immunotherapy (2023)
Sara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, Valerio Gaetano Vellone, Alessio Signori, Fabio Catalano, Alessandra Damassi, Gabriele Gaggero, Pasquale Rescigno, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Umberto Basso, Michele Milella, Olimpia Panepinto, Manlio Mencoboni, Marta Sbaraglia, Angelo Paolo Dei Tos, Veronica Murianni, Malvina Cremante, Miguel Angel Llaja Obispo, Michele Maffezzoli, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study. Cancers 15 (8) (2023)
Sara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, Valerio Gaetano Vellone, Alessio Signori, Fabio Catalano, Alessandra Damassi, Gabriele Gaggero, Pasquale Rescigno, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Umberto Basso, Michele Milella, Olimpia Panepinto, Manlio Mencoboni, Marta Sbaraglia, Angelo Paolo Dei Tos, Veronica Murianni, Malvina Cremante, Miguel Angel Llaja Obispo, Michele Maffezzoli, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study. Cancers 15 (8) (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, Ugo De Giorgi, Nicole Brighi, Giuseppe Fornarini, Chiara Tommasi, Giulia Claire Giudice, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Matteo Brunelli, Alessio Signori, Giuseppe Luigi Banna, Sebastiano Buti
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? Expert review of anticancer therapy (2023)
Veronica Murianni, Luigi Cerbone, Pasquale Rescigno, Fabio Catalano, Alessandra Damassi, Malvina Cremante, Annalice Gandini, Silvia Puglisi, Guido Pesola, Giuseppe Luigi Banna, Sebastiano Buti, Alessio Signori, Giuseppe Fornarini, Sara Elena Rebuzzi
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. Immunotherapy 14 (18) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Lorenzo Bertolotti, Federica Segato, Francesco Pagnini, Sebastiano Buti, Andrea Casarin, Antonio Celia, Francesco Ziglioli, Umberto Maestroni, Giuseppe Pedrazzi, Velio Ascenti, Chiara Martini, Calogero Cicero, Massimo De Filippo
Percutaneous Ablation of T1 Renal Masses: Comparative Local Control and Complications after Radiofrequency and Cryoablation. Diagnostics (Basel, Switzerland) 13 (19) (2023)
Satoru Taguchi, Taketo Kawai, Sebastiano Buti, Melissa Bersanelli, Yukari Uemura, Kenjiro Kishitani, Jimpei Miyakawa, Kazuma Sugimoto, Yu Nakamura, Fusako Niimi, Tomoyuki Kaneko, Jun Kamei, Daisuke Obinata, Kenya Yamaguchi, Shigenori Kakutani, Koichiro Kanazawa, Yuriko Sugihara, Mayuko Tokunaga, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Yutaka Enomoto, Hiroaki Nishimatsu, Tetsuya Fujimura, Hiroshi Fukuhara, Tohru Nakagawa, Satoru Takahashi, Haruki Kume
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab. Immunotherapy (2023)
Chiara Tommasi, Giulia Scartabellati, Diana Giannarelli, Ugo De Giorgi, Nicole Brighi, Giuseppe Fornarini, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Matteo Brunelli, Sebastiano Buti
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study. Therapeutic advances in urology 15 (2023)
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Melissa Bersanelli, Francesco Pierantoni, Ugo De Giorgi, Marilena Di Napoli, Roberto Iacovelli, Maria Giuseppa Vitale, Paola Ermacora, Andrea Malgeri, Brigida Anna Maiorano, Veronica Prati, Alessia Mennitto, Alessia Cavo, Matteo Santoni, Claudia Carella, Lucia Fratino, Giuseppe Procopio, Elena Verzoni, Daniele Santini
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). International journal of molecular sciences 24 (2) (2023)
Matteo Santoni, Javier Molina-Cerrillo, Giorgio Santoni, Elaine T Lam, Francesco Massari, Veronica Mollica, Giulia Mazzaschi, Bernardo Leon Rapoport, Enrique Grande, Sebastiano Buti
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers 15 (2) (2023)
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Alberto Clemente, Elena Verzoni, Raffaele Giusti, Marilena Di Napoli, Giuseppe Aprile, Paola Ermacora, Annamaria Catino, Vieri Scotti, Francesca Mazzoni, Pamela Francesca Guglielmini, Antonello Veccia, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casadei, Corrado Ficorella, Vincenzo Montesarchio, Francesco Verderame, Mimma Rizzo, Giorgia Guaitoli, Lucia Fratino, Caterina Accettura, Manlio Mencoboni, Fable Zustovich, Cinzia Baldessari, Saverio Cinieri, Andrea Camerini, Letizia Laera, Mariella Sorarù, Paolo Andrea Zucali, Valentina Guadalupi, Francesco Leonardi, Marcello Tiseo, Michele Tognetto, Francesco Di Costanzo, Carmine Pinto, Giorgia Negrini, Antonio Russo, Maria R Migliorino, Marco Filetti, Sebastiano Buti, null null
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). Journal for immunotherapy of cancer 9 (5) (2022)
Sara Elena Rebuzzi, Luigi Cerbone, Alessio Signori, Matteo Santoni, Veronica Murianni, Ugo De Giorgi, Giuseppe Procopio, Camillo Porta, Michele Milella, Umberto Basso, Francesco Massari, Maruzzo Marco, Roberto Iacovelli, Nicola Battelli, Luca Carmisciano, Giuseppe Luigi Banna, Sebastiano Buti, Giuseppe Fornarini
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic advances in medical oncology 14 (2022)
Giulia Airò, Michele Maffezzoli, Alessandro Lazzarin, Michele Bianconcini, Alessandro Greco, Sebastiano Buti, Alessandro Leonetti
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib. Immunotherapy 14 (16) (2022)
Matteo Brunelli, Guido Martignoni, Giorgio Malpeli, Alessandro Volpe, Luca Cima, Maria Rosaria Raspollini, Mattia Barbareschi, Alessandro Tafuri, Giulia Masi, Luisa Barzon, Serena Ammendola, Manuela Villanova, Maria Angela Cerruto, Michele Milella, Sebastiano Buti, Melissa Bersanelli, Giuseppe Fornarini, Sara Elena Rebuzzi, Valerio Gaetano Vellone, Gabriele Gaggero, Giuseppe Procopio, Elena Verzoni, Sergio Bracarda, Martina Fanelli, Roberto Sabbatini, Rodolfo Passalacqua, Bruno Perrucci, Maria Olga Giganti, Maddalena Donini, Stefano Panni, Marcello Tucci, Veronica Prati, Cinzia Ortega, Anna Caliò, Albino Eccher, Filippo Alongi, Giovanni Pappagallo, Roberto Iacovelli, Alessandra Mosca, Paolo Umari, Ilaria Montagnani, Stefano Gobbo, Francesco Atzori, Enrico Munari, Marco Maruzzo, Umberto Basso, Francesco Pierconti, Carlo Patriarca, Piergiuseppe Colombo, Alberto Lapini, Giario Conti, Roberto Salvioni, Enrico Bollito, Andrea Cossarizza, Francesco Massari, Mimma Rizzo, Renato Franco, Federica Zito-Marino, Yoseba Aberasturi Plata, Francesca Galuppini, Marta Sbaraglia, Angelo Paolo Dei Tos, Angelo Paolo Dei Tos, Maurizio Colecchia, Holger Moch, Maurizio Scaltriti, Camillio Porta, Brett Delahunt, Gianluca Giannarini, Roberto Bortolus, Pasquale Rescigno, Giuseppe Luigi Banna, Alessio Signori, Miguel Angel Llaja Obispo, Roberto Perris, Alessandro Antonelli
Validation of a Novel Three-Dimensional ( 3D Fusion ) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of personalized medicine 12 (5) (2022)
Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, Veronica Mollica, Ursula Maria Vogl, Laura Marandino, Francesco Massari, Ricardo Pereira Mestre, Elisa Zanardi, Alessio Signori, Sebastiano Buti, Matteo Bauckneht, Silke Gillessen Sommer, Giuseppe Luigi Banna, Giuseppe Fornarini
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. Cancers 14 (5) (2022)
Giuseppe Luigi Banna, Umberto Basso, Emilio Francesco Giunta, Lucia Fratino, Sara Elena Rebuzzi, Sebastiano Buti, Marco Maruzzo, Ugo De Giorgi, Veronica Murianni, Marika Cinausero, Helga Lipari, Teresa Gamba, Orazio Caffo, Davide Bimbatti, Arianna Dri, Alessandra Mosca, Paola Ermacora, Francesca Vignani, Aichi Msaki, Barbara Bonifacio, Valentina Lombardo, Vincenza Conteduca, Giuseppe Fornarini, Pasquale Rescigno
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network. Current oncology (Toronto, Ont.) 29 (10) (2022)
Sebastiano Buti, Umberto Basso, Diana Giannarelli, Ugo De Giorgi, Marco Maruzzo, Roberto Iacovelli, Luca Galli, Camillo Porta, Francesco Carrozza, Giuseppe Procopio, Giuseppe Fonarini, Giovanni Lo Re, Matteo Santoni, Roberto Sabbatini, Antonio Cusmai, Paolo Andrea Zucali, Carlo Aschele, Editta Baldini, Elena Zafarana, Adolfo Favaretto, Silvana Leo, Alketa Hamzaj, Rosanna Mirabelli, Franco Nole', Silvia Zai, Claudio Chini, Cristina Masini, Sonia Fatigoni, Andrea Rocchi, Emiliano Tamburini, Alessio Cortellini, Melissa Bersanelli
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. Journal of immunotherapy (Hagerstown, Md. : 1997) 46 (1) (2022)
Sebastiano Buti, Francesca Trentini, Pierangela Sepe, Melanie Claps, Luca Isella, Elena Verzoni, Giuseppe Procopio
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients. Tumori (2022)
Martina Catalano, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Sebastiano Buti, Giulia Mazzaschi, Giuseppe Procopio, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. Biomedicines 10 (10) (2022)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori (2022)
Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, Carlo Cattrini, Matteo Brunelli, Massimo Di Maio
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy (2021)
Melissa Bersanelli, Alessio Cortellini, Sebastiano Buti
The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the "inflamed tumor" to the "inflamed patient". Human vaccines & immunotherapeutics 17 (7) (2021)
Marco Russano, Alessio Cortellini, Raffaele Giusti, Alessandro Russo, Federica Zoratto, Francesca Rastelli, Alain Gelibter, Rita Chiari, Olga Nigro, Michele De Tursi, Sergio Bracarda, Stefania Gori, Francesco Grossi, Melissa Bersanelli, Lorenzo Calvetti, Vincenzo Di Noia, Mario Scartozzi, Massimo Di Maio, Paolo Bossi, Alfredo Falcone, Fabrizio Citarella, Francesco Pantano, Corrado Ficorella, Marco Filetti, Vincenzo Adamo, Enzo Veltri, Federica Pergolesi, Mario Alberto Occhipinti, Linda Nicolardi, Alessandro Tuzi, Pietro Di Marino, Serena Macrini, Alessandro Inno, Michele Ghidini, Sebastiano Buti, Giuseppe Aprile, Eleonora Lai, Marco Audisio, Salvatore Intagliata, Riccardo Marconcini, Davide Brocco, Giampiero Porzio, Marta Piras, Erika Rijavec, Francesca Simionato, Clara Natoli, Marcello Tiseo, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer immunology, immunotherapy : CII (2021)
Michela Verzè, Roberta Minari, Letizia Gnetti, Paola Bordi, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Maria Majori, Massimo De Filippo, Sebastiano Buti, Donatello Gasparro, Rita Nizzoli, Cinzia Azzoni, Lorena Bottarelli, Anna Squadrilli, Paola Mozzoni, Marcello Tiseo
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature. Cancers 13 (21) (2021)
Melissa Bersanelli, Diana Giannarelli, Alessandro Leonetti, Sebastiano Buti, Marcello Tiseo, Antonio Nouvenne, Andrea Ticinesi, Tiziana Meschi, Giuseppe Procopio, Riccardo Danielli
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients. Future oncology (London, England) 17 (9) (2021)
Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, Daniele Raggi, Elena Farè, Maruzzo Marco, Umberto Basso, Ugo De Giorgi, Francesca Vignani, Giuseppe Luigi Banna, Marco Stellato, Rosa Tambaro, Emanuele Naglieri, Tania Losanno, Giuseppe Procopio, Sandro Pignata, Andrea Necchi, Sebastiano Buti
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology. Immunotherapy (2021)
Alessia Mennitto, Emma Zattarin, Massimo Di Maio, Davide Bimbatti, Ugo De Giorgi, Sebastiano Buti, Daniele Santini, Chiara Casadei, Mariella Sorarù, Carlo Messina, Claudia Mucciarini, Giuseppe Di Lorenzo, Giandomenico Roviello, Consuelo Buttigliero, Marco Stellato, Pierangela Sepe, Melanie Claps, Valentina Guadalupi, Arianna Ottini, Sandro Pignata, Filippo G De Braud, Elena Verzoni, Giuseppe Procopio
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Expert review of anticancer therapy (2021)
Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna, Filippo Pederzoli, Elena Farè, Daniele Raggi, Patrizia Giannatempo, Ugo De Giorgi, Umberto Basso, Tania Losanno, Daniele Santini, Claudia Mucciarini, Marcello Tucci, Rosa Tambaro, Azzurra Farnesi, Orazio Caffo, Antonello Veccia, Emanuele Naglieri, Alberto Briganti, Giuseppe Procopio, Sandro Pignata, Andrea Necchi
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clinical Medicine Insights. Oncology 15 (2021)
Gianluca Taronna, Alessandro Leonetti, Filippo Gustavo Dall'Olio, Alessandro Rizzo, Claudia Parisi, Sebastiano Buti, Paola Bordi, Stefano Brocchi, Rita Golfieri, Andrea Ardizzoni, Nicola Sverzellati, Marcello Tiseo
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib. Tumori (2021)
Roberta Minari, Francesco Bonatti, Giulia Mazzaschi, Alessandra Dodi, Francesco Facchinetti, Francesco Gelsomino, Gloria Cinquegrani, Anna Squadrilli, Paola Bordi, Sebastiano Buti, Melissa Bersanelli, Alessandro Leonetti, Agnese Cosenza, Leonarda Ferri, Elena Rapacchi, Federico Quaini, Andrea Ardizzoni, Marcello Tiseo
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori (2021)
Sebastiano Buti, Fabiana Perrone, Teresa Zielli, Giulia Mazzaschi, Chiara Casartelli, Alessandro Leonetti, Gianluca Milanese, Mario Silva, Roberta Eufrasia Ledda, Antonino Musolino, Francesca Pucci, Melissa Bersanelli, Marcello Tiseo
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study. Clinical Medicine Insights. Oncology 15 (2021)
Melissa Bersanelli, Fausto Petrelli, Sebastiano Buti, Ignazio Stanganelli
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials. Human vaccines & immunotherapeutics (2021)
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, Maruzzo Marco, Ugo De Giorgi, Paolo Pedrazzoli, Andrea Sbrana, Paolo Andrea Zucali, Cristina Masini, Emanuele Naglieri, Giuseppe Procopio, Sara Merler, Laura Tomasello, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Stefano Panni, Veronica Mollica, Maria Sorarù, Matteo Santoni, Alessio Cortellini, Veronica Prati, Hector Josè Soto Parra, Marco Stellato, Francesco Atzori, Sandro Pignata, Carlo Messina, Marco Messina, Franco Morelli, Giuseppe Prati, Franco Nolè, Francesca Vignani, Alessia Cavo, Giandomenico Roviello, Francesco Pierantoni, Chiara Casadei, Melissa Bersanelli, Silvia Chiellino, Federico Paolieri, Matteo Perrino, Matteo Brunelli, Roberto Iacovelli, Camillo Porta, Sebastiano Buti, Giuseppe Fornarini
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic advances in medical oncology 13 (2021)
Sebastiano Buti, Pierre I Karakiewicz, Melissa Bersanelli, Umberto Capitanio, Zhe Tian, Alessio Cortellini, Satoru Taguchi, Alberto Briganti, Francesco Montorsi, Francesco Leonardi, Marco Bandini
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Scientific reports 10 (1) (2020)
Teresa Zielli, Letizia Gnetti, Sebastiano Buti
Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report. Tumori 106 (6) (2020)
Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Therapeutic advances in medical oncology 12 (2020)
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casadei, Alessio Cortellini, Francesco Verderame, Vincenzo Montesarchio, Mimma Rizzo, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Saverio Cinieri, Giorgia Negrini, Maria Banzi, Mariella Sorarù, Paolo Andrea Zucali, Gaetano Lacidogna, Antonio Russo, Nicola Battelli, Giuseppe Fornarini, Claudia Mucciarini, Sergio Bracarda, Andrea Bonetti, Debora Pezzuolo, Lucia Longo, Donata Sartori, Mauro Iannopollo, Luigi Cavanna, Fausto Meriggi, Davide Tassinari, Claudia Corbo, Angela Gernone, Veronica Prati, Simona Carnio, Pasqualina Giordano, Angela Maria Dicorato, Claudio Verusio, Francesco Atzori, Francesco Carrozza, Stefania Gori, Antonino Castro, Sara Pilotto, Vanja Vaccaro, Elisabetta Garzoli, Francesco Di Costanzo, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Michele Tognetto, Sebastiano Buti
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic advances in medical oncology 12 (2020)
Matteo Brunelli, Alessandro Tafuri, Luca Cima, Maria Angela Cerruto, Michele Milella, Andrea Zivi, Sebastiano Buti, Melissa Bersanelli, Giuseppe Fornarini, Valerio Gaetano Vellone, Sara Elena Rebuzzi, Giuseppe Procopio, Elena Verzoni, Sergio Bracarda, Roberto Sabbatini, Cinzia Baldessari, Albino Eccher, Rodolfo Passalacqua, Bruno Perrucci, Maria Olga Giganti, Maddalena Donini, Stefano Panni, Marcello Tucci, Veronica Prati, Cinzia Ortega, Anna Caliò, Filippo Alongi, Enrico Munari, Giovanni Pappagallo, Roberto Iacovelli, Alessandra Mosca, Camillo Porta, Guido Martignoni, Alessandro Antonelli
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. Journal of clinical pathology (2020)
Melissa Bersanelli, Sebastiano Buti, Mimma Rizzo
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert review of anticancer therapy 21 (4) (2020)
Luigi Cerbone, Sara Elena Rebuzzi, Elisabetta Lattanzi, Letizia Gnetti, Maria Laura Iaia, Nunziata D'Abbiero, Sebastiano Buti
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib. Immunotherapy (2020)
Melissa Bersanelli, Teresa Zielli, Fabiana Perrone, Chiara Casartelli, Fabiana Pratticò, Elena Rapacchi, Roberta Camisa, Michele Tognetto, Alberto Clemente, Diana Giannarelli, Sara Elena Rebuzzi, Alessandro Leonetti, Paola Bordi, Marcello Tiseo, Sebastiano Buti
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy. Immunotherapy 12 (15) (2020)
Filippo G Dall'Olio, Francesca Abbati, Francesco Facchinetti, Maria Massucci, Barbara Melotti, Anna Squadrilli, Sebastiano Buti, Francesca Formica, Marcello Tiseo, Andrea Ardizzoni
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. Therapeutic advances in medical oncology 12 (2020)
Maddalena Donini, Sebastiano Buti, Francesco Massari, Veronica Mollica, Alessandro Rizzo, Rodolfo Montironi, Melissa Bersanelli, Matteo Santoni
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. Expert review of anticancer therapy 20 (6) (2020)
Alessio Cortellini, Sebastiano Buti, Melissa Bersanelli, Raffaele Giusti, Fabiana Perrone, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Katia Cannita, Alessandra Tessitore, Federica Zoratto, Enzo Veltri, Francesco Malorgio, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Federica Pergolesi, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Daniela Iacono, Maria Rita Migliorino, Alain Gelibter, Mario Alberto Occhipinti, Francesco Martella, Alessandro Inno, Stefania Gori, Sergio Bracarda, Cristina Zannori, Claudia Mosillo, Alessandro Parisi, Giampiero Porzio, Domenico Mallardo, Maria Concetta Fargnoli, Marcello Tiseo, Daniele Santini, Paolo Antonio Ascierto, Corrado Ficorella
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology 9 (1) (2020)
Sebastiano Buti, Pierre I Karakiewicz, Melissa Bersanelli, Umberto Capitanio, Zhe Tian, Alessio Cortellini, Satoru Taguchi, Alberto Briganti, Francesco Montorsi, Francesco Leonardi, Marco Bandini
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Scientific reports 9 (1) (2019)
Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, Roberto Sabbatini, Alessandra Bearz, Sebastiano Buti, Umberto Basso, Manfred Mitterer, Cinzia Ortega, Paolo Bidoli, Francesco Ferraù, Lucio Crinò, Antonio Frassoldati, Paolo Marchetti, Enrico Mini, Alessandro Scoppola, Claudio Verusio, Giuseppe Fornarini, Giacomo Cartenì, Claudia Caserta, Cora N Sternberg
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (13) (2019)
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Camillio Porta, Marc R Matrana, Giacomo Cartenì, Simon J Crabb, Ugo De Giorgi, Umberto Basso, Cristina Masini, Fabio Calabrò, Maria Giuseppa Vitale, Daniele Santini, Francesco Massari, Luca Galli, Giuseppe Fornarini, Riccardo Ricotta, Sebastiano Buti, Paolo Andrea Zucali, Orazio Caffo, Franco Morelli, Francesco Carrozza, Angelo Martignetti, Alain Gelibter, Roberto Iacovelli, Alessandra Mosca, Francesco Atzori, Nuno Vau, Lorena Incorvaia, Cinzia Ortega, Marina Scarpelli, Antonio López-Beltran, Liang Cheng, Vittorio Paolucci, Jeffrey Graham, Erin Pierce, Sarah Scagliarini, Pierangela Sepe, Elena Verzoni, Sara Merler, Mimma Rizzo, Giulia Sorgentoni, Alessandro Conti, Francesco Piva, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Cancers 12 (1) (2019)
Matteo Santoni, Alessandro Conti, Francesco Massari, Vincenzo Di Nunno, Luca Faloppi, Eva Galizia, Jarno Morbiducci, Francesco Piva, Sebastiano Buti, Roberto Iacovelli, Benedetta Ferretti, Alessia Cimadamore, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert review of cardiovascular therapy 17 (12) (2019)
Sara Elena Rebuzzi, Fabiana Perrone, Melissa Bersanelli, Giacomo Bregni, Michele Milella, Sebastiano Buti
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert review of molecular diagnostics 20 (2) (2019)
Sebastiano Buti
A new prognostic model for localized renal cell carcinoma. World journal of urology 37 (1) (2018)